Related Experiment Video
Updated: May 19, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
CD133 marks for colorectal adenocarcinoma
Man-Fong Chew1, Kean-Hooi Teoh, Phaik-Leng Cheah
1Department of Pathology, Faculty of Medicine, University of Malaya.
The Malaysian Journal of Pathology
|August 9, 2012
Summary
CD133 is frequently expressed in colorectal adenocarcinoma, unlike benign tissue. Further research is needed to confirm if CD133 marks colorectal cancer stem cells.
Area of Science:
- Oncology
- Pathology
Background:
- CD133 is a frequently studied marker in colorectal cancer.
- It has been advocated as a marker for colorectal carcinoma stem cells.
Purpose of the Study:
- To determine the expression of CD133 in colorectal adenocarcinoma.
- To compare CD133 expression in malignant tissue versus adjacent benign colorectal epithelium.
Main Methods:
- Immunohistochemical staining for CD133 on 56 archived colorectal adenocarcinoma samples.
- Semi-quantitation of CD133 immunopositivity (proportion and intensity).
- Comparison of CD133 expression scores between malignant and benign tissues.
Main Results:
- CD133 expression was significantly increased in colorectal adenocarcinoma (87.5%) compared to benign epithelium (26.8%).
- Colorectal adenocarcinoma had a significantly higher mean immunopositivity score (8.5) than benign epithelium (0.5).
- A higher proportion of colorectal adenocarcinoma samples showed scores >4 compared to benign tissues.
Conclusions:
- CD133 expression is significantly elevated in colorectal adenocarcinoma.
- CD133 can mark colorectal adenocarcinoma.
- It remains unclear if CD133 is a definitive marker for colorectal cancer stem cells.
